# Researcher Competency Assessment in Pharma R&D: A New Approach
The average cost to bring a new drug to market reached $2.6 billion in 2024, according to the Tufts Center for the Study of Drug Development. Clinical trial failures account for the majority of this cost, and a significant fraction of trial failures trace to avoidable protocol design errors, statistical analysis mistakes, and regulatory submission deficiencies — all of which are competency issues.
The Unassessed Competency Risk
Pharma R&D organizations hire PhDs and MDs with exceptional scientific credentials. What they do not systematically assess is operational research competency: the ability to design protocols that will survive regulatory scrutiny, select statistical methods appropriate for the endpoint structure, manage CRO relationships effectively, and navigate the regulatory pathway for the specific indication.
These competencies are assumed based on credentials and experience. The assumption fails often enough to be expensive:
What R&D Competency Assessment Should Cover
**Protocol design proficiency**: Can the researcher design a protocol with appropriate inclusion/exclusion criteria, endpoint selection, sample size justification, and operational feasibility? Simulation-based assessment items present clinical scenarios and evaluate protocol design decisions.
**Biostatistics competency**: Beyond knowing statistical methods, can the researcher select the appropriate method for a given data structure? Can they interpret interim analysis results correctly? Can they identify when a pre-specified analysis plan needs modification versus when post-hoc analysis is appropriate?
**Regulatory pathway knowledge**: Does the researcher understand the differences between 505(b)(1), 505(b)(2), and 351(k) pathways? Can they anticipate FDA advisory committee questions? Do they understand ICH E6(R3) GCP requirements?
**GxP compliance awareness**: Good Clinical Practice, Good Laboratory Practice, and Good Manufacturing Practice requirements are foundational but frequently misunderstood in specific application. Assessment items can present GxP scenarios with nuanced compliance decisions.
**Data integrity and ALCOA+ principles**: With increasing FDA focus on data integrity (80+ warning letters citing data integrity in 2024), researcher understanding of Attributable, Legible, Contemporaneous, Original, and Accurate data practices is assessable and critical.
Adaptive Assessment for Research Teams
Research competency spans a wide range of experience levels — from newly hired associate scientists to senior directors with 20+ years of experience. Adaptive assessment adjusts to each researcher's level:
The adaptive engine converges on each researcher's precise competency level in 25-35 items per domain, producing a proficiency report that identifies specific gaps for targeted development.
Integration With R&D Quality Systems
Assessment results must integrate with the organization's quality management system:
The Business Case
For a pharma company with 500 R&D professionals:
**QLM's adaptive assessment engine provides pharma R&D competency measurement with protocol design simulations, biostatistics proficiency testing, and GxP compliance assessment.** Learn more at [quantumlearningmachines.com](https://quantumlearningmachines.com).